Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Non-cash Items (2016 - 2025)

Sutro Biopharma (STRO) has disclosed Non-cash Items for 10 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items changed N/A to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $1.2 million for FY2025, N/A changed from the prior year.
  • Non-cash Items hit $1.2 million in Q4 2025 for Sutro Biopharma, down from $5.2 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $58.1 million in Q1 2021 to a low of $180000.0 in Q4 2023.
  • Historically, Non-cash Items has averaged $11.0 million across 5 years, with a median of $5.7 million in 2023.
  • Biggest five-year swings in Non-cash Items: soared 2897.04% in 2021 and later plummeted 99.27% in 2022.
  • Year by year, Non-cash Items stood at $15.0 million in 2021, then tumbled by 85.38% to $2.2 million in 2022, then plummeted by 91.77% to $180000.0 in 2023, then surged by 3427.65% to $6.3 million in 2024, then tumbled by 80.72% to $1.2 million in 2025.
  • Business Quant data shows Non-cash Items for STRO at $1.2 million in Q4 2025, $5.2 million in Q3 2025, and $6.6 million in Q2 2025.